Topical administration of DPP-IV inhibitors prevents retinal neurodegeneration in experimental diabetes

Diabetologia

Volumn 60, Issue 11, 2017, Pages 2285-2298

  Hernández, Cristina ^a,b   Bogdanov, Patricia ^a,b   Solà Adell, Cristina ^a,b   Sampedro, Joel ^a   Valeri, Marta ^a   Genís, Xavier ^c   Simó Servat, Olga ^a,b   García Ramírez, Marta ^a,b   Simó, Rafael ^a,b  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c Instituto de Investigación Germans Trias I Pujol   (Spain)

Author keywords

Diabetic retinopathy; DPP IV inhibitors; Experimental diabetes; GLP 1; Retinal neurodegeneration

Indexed keywords

ALBUMIN; COLLAGEN TYPE 4; DIPEPTIDYL PEPTIDASE IV; EVANS BLUE; EXCITATORY AMINO ACID TRANSPORTER; GLIAL FIBRILLARY ACIDIC PROTEIN; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; GLUTAMIC ACID; IONISED CALCIUM BINDING ADAPTOR MOLECULE 1; MESSENGER RNA; PROTEIN AIF1; PROTEIN EPAC1; PROTEIN IBA1; SAXAGLIPTIN; SITAGLIPTIN; UNCLASSIFIED DRUG; ADAMANTANE; DIPEPTIDE; DIPEPTIDYL PEPTIDASE IV INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL ACTIVATION; CLINICAL ARTICLE; CONTROLLED STUDY; ELECTRORETINOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPERIMENTAL DIABETES MELLITUS; FEMALE; GLUCOSE BLOOD LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNOFLUORESCENCE TEST; INTERVENTION STUDY; MALE; MOUSE; NERVE DEGENERATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN DEGRADATION; PROTEIN EXPRESSION; RETINA DEGENERATION; RETINAL PIGMENT EPITHELIUM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT DURATION; VITREOUS BODY; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; ANIMAL; DRUG EFFECT; IMMUNOHISTOCHEMISTRY; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; RETINA;

ADAMANTANE; ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DIPEPTIDES; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; ELECTRORETINOGRAPHY; GLUCAGON-LIKE PEPTIDE 1; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICE; RETINA; SITAGLIPTIN PHOSPHATE;

EID: 85026802542     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-017-4388-y     Document Type: Article

References (41)

1. Simó R, Hernández C (2015) Novel approaches for treating diabetic retinopathy based on recent pathogenic evidence. Prog Retin Eye Res 48:160–180
2. Stitt AW, Curtis TM, Chen M et al (2016) The progress in understanding and treatment of diabetic retinopathy. Prog Retin Eye Res 51:156–186
3. Simó R, Hernández C, European Consortium for the Early Treatment of Diabetic Retinopathy (EUROCONDOR) (2012) Neurodegeneration is an early event in diabetic retinopathy: therapeutic implications. Br J Ophthalmol 96:1285–1290
4. Antonetti DA, Klein R, Gardner TW (2012) Diabetic retinopathy. N Engl J Med 366:1227–1239
5. Abcouwer SF, Gardner TW (2014) Diabetic retinopathy: loss of neuroretinal adaptation to the diabetic metabolic environment. Ann N Y Acad Sci 1311:174–190
6. Simó R, Hernández C, European Consortium for the Early Treatment of Diabetic Retinopathy (EUROCONDOR) (2014) Neurodegeneration in the diabetic eye: new insights and therapeutic perspectives. Trends Endocrinol Metab 25:23–33
7. Carrasco E, Hernández C, Miralles A, Huguet P, Farrés J, Simó R (2007) Lower somatostatin expression is an early event in diabetic retinopathy and is associated with retinal neurodegeneration. Diabetes Care 30:2902–2908
8. Garcia-Ramírez M, Hernández C, Villarroel M et al (2009) Interphotoreceptor retinoid-binding protein (IRBP) is downregulated at early stages of diabetic retinopathy. Diabetologia 52:2633–2641
9. Hernández C, Bogdanov P, Corraliza L et al (2016) Topical administration of GLP-1 receptor agonists prevents retinal neurodegeneration in experimental diabetes. Diabetes 65:172–187
10. Holst JJ (2007) The physiology of glucagon-like peptide 1. Physiol Rev 87:1409–1439
11. Hernández C, García-Ramírez M, Corraliza L et al (2013) Topical administration of somatostatin prevents retinal neurodegeneration in experimental diabetes. Diabetes 62:2569–2578
12. Marmor MF, Holder GE, Seeliger MW, Yamamoto S, International Society for Clinical Electrophysiology of Vision (2004) Standard for clinical electroretinography (2004 update). Doc Ophthalmol 108:107–114
13. Bogdanov P, Corraliza L, Villena JA et al (2014) The db/db mouse: a useful model for the study of diabetic retinal neurodegeneration. PLoS One 9:e97302
14. Anderson PJ, Watts H, Hille C et al (2008) Glial and endothelial blood-retinal barrier responses to amyloid-beta in the neural retina of the rat. Clin Ophthalmol 2:801–816
15. Xu Q, Qaum T, Adamis AP (2001) Sensitive blood–retinal barrier breakdown quantitation using Evans blue. Invest Ophthalmol Vis Sci 42:789–794
16. Xu H, Forrester JV, Liversidge J, Crane I (2003) Leukocyte trafficking in experimental autoimmune uveitis: breakdown of blood-retinal barrier and upregulation of cellular adhesion molecules. J Invest Ophthalmol Vis Sci 44:226–234
17. Anand-Apte B, Ebrahem Q, Cutler A et al (2010) Betacellulin induces increased retinal vascular permeability in mice. PLoS One 5:e13444
18. Schindelin J, Arganda-Carreras I, Frise E et al (2012) Fiji: an open-source platform for biological-image analysis. Nat Methods 9:676–682
19. Narayan SB, Ditewig-Meyers G, Graham KS, Scott R, Bennett MJ (2011) Measurement of plasma amino acids by ultraperformance liquid chromatography. Clin Chem Lab Med 49:1177–1185
20. de Rooij J, Zwartkruis FJ, Verheijen MH et al (1998) Epac is a Rap1 guanine-nucleotide-exchange factor directly activated by cyclic AMP. Nature 396:474–477
21. Kooistra MR, Corada M, Dejana E, Bos JL (2005) Epac1 regulates integrity of endothelial cell junctions through VE-cadherin. FEBS Lett 579:4966–4972
22. Breckler M, Berthouze M, Laurent AC, Crozatier B, Morel E, Lezoualc’h F (2011) Rap-linked cAMP signaling Epac proteins: compartmentation, functioning and disease implications. Cell Signal 23:1257–1266
23. Birukova AA, Tian Y, Dubrovskyi O et al (2012) VE-cadherin trans-interactions modulate Rac activation and enhancement of lung endothelial barrier by iloprost. J Cell Physiol 227:3405–3416
24. Boddu SHS, Gupta H, Patel S (2014) Drug delivery to the back of the eye following topical administration: an update on research and patenting activity. Recent Pat Drug Deliv Formul 8:27–36
25. Simó R, Hernández C (2017) GLP-1 as a target for the treatment of diabetic retinopathy: friend or foe? Diabetes 66:1–8
26. Dietrich N, Kolibabka M, Busch S et al (2016) The DPP4 inhibitor linagliptin protects from experimental diabetic retinopathy. PLoS One 11:e0167853
27. Wronkowitz N, Görgens SW, Romacho T et al (2014) Soluble DPP4 induces inflammation and proliferation of human smooth muscle cells via protease-activated receptor 2. Biochim Biophys Acta 1842:1613–1621
28. Zhang H, Maqsudi S, Rainczuk A et al (2015) Identification of novel dipeptidyl peptidase 9 substrates by two-dimensional differential in-gel electrophoresis. FEBS J 282:3737–3757
29. Gonçalves A, Leal E, Paiva A et al (2012) Protective effects of the dipeptidyl peptidase IV inhibitor sitagliptin in the blood-retinal barrier in a type 2 diabetes animal model. Diabetes Obes Metab 14:454–463
30. Maeda S, Yamagishi S, Matsui T et al (2013) Beneficial effects of vildagliptin on retinal injury in obese type 2 diabetic rats. Ophthalmic Res 50:221–226
31. Gonçalves A, Marques C, Leal E et al (2014) Dipeptidyl peptidase-IV inhibition prevents blood retinal barrier breakdown, inflammation and neuronal cell death in the retina of type 1 diabetic rats. Biochim Biophys Acta 1842:1454–1463
32. Lee CS, Kim YG, Cho HJ et al (2016) Dipeptidyl peptidase-4 inhibitor increases vascular leakage in retina through VE-cadherin phosphorylation. Sci Rep 6:29393
33. Ott C, Raff U, Schmidt S et al (2014) Effects of saxagliptin on early microvascular changes in patients with type 2 diabetes. Cardiovasc Diabetol 13:19
34. Marso SP, Bain SC, Consoli A et al (2016) Semaglutide in cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 375:1834–1844
35. Zhang Y, Wang Q, Zhang J, Lei X, Xu G-T, Ye W (2009) Protection of exendin-4 analogue in early experimental diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 247:699–706
36. Zhang Y, Zhang J, Wang Q et al (2011) Intravitreal injection of exendin-4 analogue protects retinal cells in early diabetic rats. Invest Ophthalmol Vis Sci 52:278–285
37. Fu Z, Kuang HY, Hao M, Gao XY, Liu Y, Shao N (2012) Protection of exenatide for retinal ganglion cells with different glucose concentrations. Peptides 37:25–31
38. Fan Y, Liu K, Wang Q, Ruan Y, Zhang Y, Ye W (2014) Exendin-4 protects retinal cells from early diabetes in Goto-Kakizaki rats by increasing the Bcl-2/Bax and Bcl-xL/Bax ratios and reducing reactive gliosis. Mol Vis 10:1557–1568
39. Fan Y, Liu K, Wang Q, Ruan Y, Ye W, Zhang Y (2014) Exendin-4 alleviates retinal vascular leakage by protecting the blood-retinal barrier and reducing retinal vascular permeability in diabetic Goto-Kakizaki rats. Exp Eye Res 127:104–116
40. Zeng Y, Yang K, Wang F et al (2016) The glucagon like peptide 1 analogue, exendin-4, attenuated oxidative stress-induced retinal cell death in early diabetic rats through promoting Sirt1 and Sirt3 expression. Exp Eye Res 151:203–211
41. The Diabetes Control and Complications Trial Research Group (1998) Early worsening of diabetic retinopathy in the Diabetes Control and Complications Trial. Arch Ophthalmol 116:874–886